O-(3-morpholin-4-yl-propyl)-hydroxylamine | 127437-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: O-(3-morpholin-4-yl-propyl)-hydroxylamine
• 英文别名: 4-[3-(aminooxy)propyl]Morpholine；O-(3-morpholin-4-ylpropyl)hydroxylamine
• CAS: 127437-49-4
• 化学式: C₇H₁₆N₂O₂
• mdl: MFCD11613807
• 分子量: 160.216
• InChiKey: YVPBGTVQPKQWDV-UHFFFAOYSA-N

物化性质

• 沸点：
  289.3±25.0 °C(Predicted)
• 密度：
  1.049±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  47.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  O-(3-morpholin-4-yl-propyl)-hydroxylamine 、 1-[4-(1-methyl-5-nitro-1H-imidazol-2-ylmethoxy)-phenyl]-ethanone 在 溶剂黄146 作用下， 生成 1-[4-(1-methyl-5-nitro-1H-imidazol-2-ylmethoxy)-phenyl]-ethanone O-(3-morpholin-4-yl-propyl)-oxime
  参考文献：
  名称：

  Winkelman; Raether; Gebert, Arzneimittel-Forschung/Drug Research, 1978, vol. 28, # 10, p. 1682 - 1684

  摘要：

  DOI：

文献信息

• [EN] FUNGICIDAL OXIMES AND HYDRAZONES<br/>[FR] OXIMES ET HYDRAZONES FONGICIDES
  申请人：DU PONT

  公开号：WO2011146182A1

  公开（公告）日：2011-11-24

  Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein E, X, G, W2 and Z are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention. Also disclosed are compounds of Formula 1A including all stereoisomers, N-oxides, and salts thereof, wherein E, X, G and Z1 are as defined in the disclosure. Also disclosed is the use of the compounds of Formula 1A as intermediates for preparing compounds of Formula 1.

  揭示了Formula 1的化合物，包括所有立体异构体、N-氧化物和盐类，其中E、X、G、W2和Z如披露中所定义。还披露了含有Formula 1化合物的组合物以及用于控制由真菌病原体引起的植物疾病的方法，包括施用本发明的化合物或组合物的有效量。还披露了包括所有立体异构体、N-氧化物和盐类的Formula 1A的化合物，其中E、X、G和Z1如披露中所定义。还披露了将Formula 1A的化合物用作制备Formula 1化合物的中间体的用途。
• [EN] 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINOPYRIDO[2,3-D]PYRIMIDINE A DISUBSTITUTION 5,7
  申请人：ABBOTT LAB

  公开号：WO2000023444A1

  公开（公告）日：2000-04-27

  A method of inhibiting adenosine kinase by administering one of more compounds of formula (I), wherein R?1, R2, R3 and R4¿ are defined, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R?1, R2, R3 and R4¿ are separately defined.

  一种通过给予式(I)中的一个或多个化合物来抑制腺苷激酶的方法，其中R1、R2、R3和R4被定义，以及包含上述化合物的治疗有效量与药学可接受载体组合的制药组合物，以及一种治疗哺乳动物的脑缺血、癫痫、疼痛感知、炎症和败血症的方法，包括给予哺乳动物上述化合物的治疗有效量，制备上述化合物的方法以及具有上述式中R1、R2、R3和R4分别被定义的化合物。
• 2-Azetidinone derivatives
  申请人：TAISHO PHARMACEUTICAL CO. LTD

  公开号：EP0365364A2

  公开（公告）日：1990-04-25

  2-Azetizinone derivatives, useful as blood platelet aggregation inhibiting agents, are those of the formula: in which R1 is a halogen atom a C1-C4 alkyl group, a C1-C4 alkoxy group or an alkoxycarbonyl group in which the alkoxy group is a C1-C4 alkoxy group; R2 is a group of the formula: (in which R3 and R4 are the same or different and each is a hydrogen atom, a C1-C5 alkenyl group, a phenyl group or a benzyl group), a group of the formula: (in which R5 is a hydrogen atom, a phenyl group substituted by a halogen atom or a C1-C4 alkoxy group, a phenyl group, a C1-C4 alkyl group or a pyridyl group), a group of the formula: (in which R6 is a hydrogen atom, a Ci-C4 alkyl group or a benzyl group and R7 is a hydrogen atom or a C1-C4 alkyl group), a group of the formula: (in which R8 and R9 are the same or different and each is a hydrogen atom or C1-C4 alkyl group), a pyrrolidinyl group or a tetrahydroazepinyl group; and n is an integer of from 2 to 10; and salts thereof.

  可用作血小板聚集抑制剂的 2-氮杂环丁酮衍生物是式中的衍生物： 其中 R1 是卤素原子、C1-C4 烷基、C1-C4 烷氧基或烷氧基羰基，其中烷氧基是 C1-C4 烷氧基；R2 是式中的一个基团： (其中 R3 和 R4 相同或不同，且各自为氢原子、C1-C5 烯基、苯基或苄基）、式中的基团： (其中 R5 为氢原子、被卤素原子或 C1-C4 烷氧基取代的苯基、苯基、C1-C4 烷基或吡啶基）、式中的一个基团： (其中 R6 为氢原子、Ci-C4 烷基或苄基，R7 为氢原子或 C1-C4 烷基）、式中的一个基团： (其中 R8 和 R9 相同或不同，且各自为氢原子或 C1-C4 烷基）、吡咯烷基团或四氢氮杂卓基团；以及 n 为 2 至 10 的整数；及其盐类。
• NOVEL HALO-(3-(PHENYLSULFONYL)PROP-1-ENYL)PYRIDINE DERIVATIVE AND USE THEREOF
  申请人：Korea Institute of Science and Technology

  公开号：EP3838896A1

  公开（公告）日：2021-06-23

  The present invention relates to a novel halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative or a pharmaceutically acceptable salt thereof; a preparation method thereof; and an Nrf2 activator and a pharmaceutical composition for preventing or treating diseases induced by a decrease in Nrf2 activity, both of which comprise the same as an active ingredient.

  本发明涉及一种新型卤代-(3-(苯磺酰基)丙-1-烯基)吡啶衍生物或其药学上可接受的盐；其制备方法；以及一种 Nrf2 激活剂和一种用于预防或治疗因 Nrf2 活性降低而诱发的疾病的药物组合物，二者均包含相同的活性成分。
• Coronelli; Lancini; Pallanza, Farmaco, Edizione Scientifica, 1966, vol. 21, # 6, p. 450 - 463
  作者：Coronelli、Lancini、Pallanza、Tamoni、Sensi

  DOI：——

  日期：——